Mesa Laboratories Inc

Mesa Laboratories has a market price of $96.47, yielding a market cap of $532.98 million and a price-to-book ratio of 3.33. The company's liquidity position is characterized by $27.32 million in cash and equivalents, but with $177.95 million in long-term debt, the net cash position is negative. The debt-to-equity ratio of 1.11 and a current ratio of 0.63 indicate moderate leverage and liquidity risk. Profitability metrics show a return on equity of -1.24% and a return on assets of -0.46%, both below the industry median for medical equipment and services. The company reported a net loss of $1.97 million despite $240.98 million in revenue, with an operating income of $19.22 million. Gross profit of $152.10 million represents 63.1% of revenue, which is in line with industry norms. The company's revenue is concentrated in the United States, with no disclosed international operations. It operates in a single business segment focused on diagnostic testing and laboratory services. The capital structure is dominated by long-term debt, with no material revenue diversification across geographic or product segments. Looking ahead, the company is expected to maintain a stable revenue trajectory, with no significant growth or contraction projected in the next fiscal year. Free cash flow of $14.59 million and capital expenditures of $4.50 million suggest a modest reinvestment rate. However, the net loss and negative return on equity raise concerns about long-term profitability. The risk assessment highlights liquidity as a medium concern, with a negative net cash position after subtracting total debt. Dilution risk is low, and no recent equity issuance or dilutive events have been reported. The company's financial leverage and negative returns on equity are key risk factors. Recent filings and transcripts indicate no material changes in business strategy or operations. The company continues to focus on diagnostic testing and laboratory services, with no new product launches or geographic expansions disclosed in the latest reports.